Clinical trials
Active, not recruiting Observational trials in the Netherlands
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
180 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2007 | 1 |
| 2009 | 1 |
| 2010 | 3 |
| 2012 | 1 |
| 2013 | 5 |
| 2014 | 4 |
| 2015 | 3 |
| 2016 | 3 |
| 2017 | 10 |
| 2018 | 8 |
| 2019 | 20 |
| 2020 | 15 |
| 2021 | 29 |
| 2022 | 31 |
| 2023 | 22 |
| 2024 | 16 |
| 2025 | 7 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Active, not recruiting | 180 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Erasmus Medical Center | 10 |
| Maastricht Radiation Oncology | 7 |
| Maastricht University Medical Center | 7 |
| Radboud University Medical Center | 7 |
| University Medical Center Groningen | 7 |
| Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 6 |
| Leiden University Medical Center | 6 |
| AbbVie | 5 |
| Boston Scientific Corporation | 4 |
| W.L.Gore & Associates | 4 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cardiovascular Diseases | 7 |
| Aortic Valve Stenosis | 5 |
| Arthritis, Rheumatoid | 5 |
| Crohn Disease | 5 |
| Aneurysm | 4 |
| Aortic Aneurysm, Abdominal | 4 |
| Aortic Aneurysm, Thoracic | 4 |
| Hip Fractures | 4 |
| Lung Neoplasms | 4 |
| Osteoarthritis | 4 |
Trials
Showing 1 to 25 of 180. Each trial links to its page on Pharma Observatory.
80 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.